For ROS1+ NSCLC, albeit assessed in the separate trials NCT03612154, TRIDENT I, and EUCROSS, the third- and fourth-generation ROS1 inhibitors lorlatinib and repotrectinib yielded far better results than crizotinib (PFS 35.8 and 35.7 months, respectively, vs 9–20 months, Table 3). Here, ROS1 is linked to non-small cell lung carcinoma.